BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine. The vaccine has been distributed internationally, giving BioNTech a global commercial presence through partnerships and regulatory approvals in multiple geographies. The company was founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber; Şahin serves as chief executive officer and Türeci serves as chief medical officer.

Key Stats

• Today's Range: $85.00 to $87.27
• 50-Day Range: $86.86 to $116.57
• 52-Week Range: $79.52 to $124.00
• Volume: 1.08 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $125.80
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 89% of companies evaluated by MarketBeat, and ranked 49th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

BioNTech has a consensus price target of $125.80, representing about 44.5% upside from its current price of $87.06.

Amount of Analyst Coverage

BioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioNTech are expected to grow in the coming year, from ($6.62) to ($5.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioNTech is -11.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioNTech is -11.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 2.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNTech has recently decreased by 9.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.09

News Sentiment

BioNTech has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for BioNTech this week, compared to 8 articles on an average week.

Search Interest

Only 8 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

5 people have added BioNTech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,246,837.00 in company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.52% of the stock of BioNTech is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/28/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BNTX
• CIK: 1776985
• Web: www.biontech.com
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 7,807
• Year Founded: 2008

Price Target and Rating

• Average Price Target for BioNTech: $125.80
• High Price Target: $155.00
• Low Price Target: $94.00
• Potential Upside/Downside: +44.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.68
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 204,330,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A